Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30333541.
- Also identified by DOI 10.1038/s41395-018-0368-1.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Infliximab for inflammatory bowel disease (IBD) is FDA-approved to be administered 2 h or more. We adopted a new protocol to infuse infliximab over 1 h and in this study, we aimed to determine the safety of a 1-h infusion. This retrospective cohort included adult IBD patients who received infliximab between June and December 2017 and compared reaction rates of 1-h maintenance infusions to that of 2-h maintenance infusions. A total of 551 infusions were administered to 179 patients. The infusion groups demonstrated no significant differences in reaction rates. Infliximab infusion over 1 h is well-tolerated.
Medical subject headings
- Gastrointestinal Agents
- Inflammatory Bowel Diseases
- Infliximab
- Infusions, Intravenous
- Injection Site Reaction